ClinicalTrials.Veeva

Menu

Gemcitabine With Curcumin for Pancreatic Cancer

R

Rambam Health Care Campus

Status and phase

Completed
Phase 2

Conditions

Pancreatic Cancer

Treatments

Drug: curcumin (+ gemcitabine)

Study type

Interventional

Funder types

Other

Identifiers

NCT00192842
RonCurcuminPancreas.CTIL

Details and patient eligibility

About

The study hypotheasis is that curcumin, a natural compound with a potent antiproliferative effect, can improve the efficacy of the standard chemotherapy gemcitabine in patients with advanced pancreatic cancer. That is why the patients are given a daily oral dose of 8 gr of curcumin along the chemotherapeutic protocol of weekly gemcitabine.

Enrollment

17 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • locally advanced or metastatic adenocarcinoma of the pancreas
  • no prior chemotherapy
  • performance status 0-2
  • adequate hematology and chemistry

Exclusion criteria

  • serious concurrent medical condition

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems